Aptamer Group
@aptamergroup.bsky.social
We develop Optimer® binders to enable innovation across research, diagnostics, therapeutics and bioprocessing.
Tired of batch variability ruining your research? 🧪
Optimer® binders are chemically synthesised for total consistency across lots. No more re-standardisation, just reproducible data you can trust.
aptamergroup.com/download/311...
Optimer® binders are chemically synthesised for total consistency across lots. No more re-standardisation, just reproducible data you can trust.
aptamergroup.com/download/311...
February 16, 2026 at 1:04 PM
Tired of batch variability ruining your research? 🧪
Optimer® binders are chemically synthesised for total consistency across lots. No more re-standardisation, just reproducible data you can trust.
aptamergroup.com/download/311...
Optimer® binders are chemically synthesised for total consistency across lots. No more re-standardisation, just reproducible data you can trust.
aptamergroup.com/download/311...
Gemini said
Struggling with binder pairs? 🧬
Optimer® ELISA pairs are identified simultaneously to save you time.
See how: aptamergroup.com/aptamer-apta...
Struggling with binder pairs? 🧬
Optimer® ELISA pairs are identified simultaneously to save you time.
See how: aptamergroup.com/aptamer-apta...
February 12, 2026 at 9:04 AM
Gemini said
Struggling with binder pairs? 🧬
Optimer® ELISA pairs are identified simultaneously to save you time.
See how: aptamergroup.com/aptamer-apta...
Struggling with binder pairs? 🧬
Optimer® ELISA pairs are identified simultaneously to save you time.
See how: aptamergroup.com/aptamer-apta...
We're delighted to announce that our Optimer® technology is included in a newly launched library preparation kit
aptamergroup.com/optimer-tech...
aptamergroup.com/optimer-tech...
February 11, 2026 at 7:03 AM
We're delighted to announce that our Optimer® technology is included in a newly launched library preparation kit
aptamergroup.com/optimer-tech...
aptamergroup.com/optimer-tech...
We're hiring for an Oligonucleotide Synthesis Manager. 🧑🔬🧬🧪
Join us and bring your aptamer synthesis powers to help deliver the next generation of diagnostics and therapeutics.
aptamergroup.com/careers/synt...
Join us and bring your aptamer synthesis powers to help deliver the next generation of diagnostics and therapeutics.
aptamergroup.com/careers/synt...
January 26, 2026 at 10:26 AM
We're hiring for an Oligonucleotide Synthesis Manager. 🧑🔬🧬🧪
Join us and bring your aptamer synthesis powers to help deliver the next generation of diagnostics and therapeutics.
aptamergroup.com/careers/synt...
Join us and bring your aptamer synthesis powers to help deliver the next generation of diagnostics and therapeutics.
aptamergroup.com/careers/synt...
Explore our Optimer Platform!🧬
1 platform. 3 parallel discovery processes. Unlimited solutions with antibody alternatives for your life science needs.
t.co/O0LnJC2nV6
1 platform. 3 parallel discovery processes. Unlimited solutions with antibody alternatives for your life science needs.
t.co/O0LnJC2nV6
December 18, 2025 at 1:18 PM
Explore our Optimer Platform!🧬
1 platform. 3 parallel discovery processes. Unlimited solutions with antibody alternatives for your life science needs.
t.co/O0LnJC2nV6
1 platform. 3 parallel discovery processes. Unlimited solutions with antibody alternatives for your life science needs.
t.co/O0LnJC2nV6
We’ve levelled up! 🥇
🧬 Our ISO 9001 certification now covers synthesis, ensuring top quality across everything from internal development to custom aptamer and oligo synthesis. 🧬💎
Looking for synthesis support? We’ve got you. 🤝
🧬 Our ISO 9001 certification now covers synthesis, ensuring top quality across everything from internal development to custom aptamer and oligo synthesis. 🧬💎
Looking for synthesis support? We’ve got you. 🤝
October 9, 2025 at 10:19 AM
We’ve levelled up! 🥇
🧬 Our ISO 9001 certification now covers synthesis, ensuring top quality across everything from internal development to custom aptamer and oligo synthesis. 🧬💎
Looking for synthesis support? We’ve got you. 🤝
🧬 Our ISO 9001 certification now covers synthesis, ensuring top quality across everything from internal development to custom aptamer and oligo synthesis. 🧬💎
Looking for synthesis support? We’ve got you. 🤝
Hear what our customers are experiencing with Optimer technology.
⚡ Superior performance from day one
✅ Ready to use with minimal optimisation
🧬 Outperforming traditional antibodies
Ready to experience the Optimer advantage in your research? Get in touch to learn more.
⚡ Superior performance from day one
✅ Ready to use with minimal optimisation
🧬 Outperforming traditional antibodies
Ready to experience the Optimer advantage in your research? Get in touch to learn more.
October 3, 2025 at 8:22 AM
Hear what our customers are experiencing with Optimer technology.
⚡ Superior performance from day one
✅ Ready to use with minimal optimisation
🧬 Outperforming traditional antibodies
Ready to experience the Optimer advantage in your research? Get in touch to learn more.
⚡ Superior performance from day one
✅ Ready to use with minimal optimisation
🧬 Outperforming traditional antibodies
Ready to experience the Optimer advantage in your research? Get in touch to learn more.
Technical update from Aptamer Group – Dr David Bunka shares the latest data & innovations. 6pm BST today. Register: turnerpope.com/register/
August 14, 2025 at 8:30 AM
Technical update from Aptamer Group – Dr David Bunka shares the latest data & innovations. 6pm BST today. Register: turnerpope.com/register/
Results of the General Meeting are now available.
To see the results, please head over to our Investor relations reports and presentation page.
aptamergroup.com/investors/re...
To see the results, please head over to our Investor relations reports and presentation page.
aptamergroup.com/investors/re...
July 24, 2025 at 11:13 AM
Results of the General Meeting are now available.
To see the results, please head over to our Investor relations reports and presentation page.
aptamergroup.com/investors/re...
To see the results, please head over to our Investor relations reports and presentation page.
aptamergroup.com/investors/re...
The circular and information on the general meeting for shareholders, regarding the proposed placing of £2m, is available on our website: polaris.brighterir.com/public/aptam...
July 8, 2025 at 6:11 AM
The circular and information on the general meeting for shareholders, regarding the proposed placing of £2m, is available on our website: polaris.brighterir.com/public/aptam...
We have successfully raised £2M. This will accelerate:
- Licensing discussions
- Manufacturing
- Biomarker discovery service launch
- Animal models for liver fibrosis delivery
- AI/ML integration into Optimer
polaris.brighterir.com/public/aptam...
- Licensing discussions
- Manufacturing
- Biomarker discovery service launch
- Animal models for liver fibrosis delivery
- AI/ML integration into Optimer
polaris.brighterir.com/public/aptam...
July 4, 2025 at 6:08 AM
We have successfully raised £2M. This will accelerate:
- Licensing discussions
- Manufacturing
- Biomarker discovery service launch
- Animal models for liver fibrosis delivery
- AI/ML integration into Optimer
polaris.brighterir.com/public/aptam...
- Licensing discussions
- Manufacturing
- Biomarker discovery service launch
- Animal models for liver fibrosis delivery
- AI/ML integration into Optimer
polaris.brighterir.com/public/aptam...
We've made great progress in the development of the Optimer delivery vehicle targeting liver fibrosis:
🔬 Identification of a novel biomarker targeted by Optimer for liver fibrosis therapies
🧬 Reduction in scar tissue formation in liver fibrosis models
👉 polaris.brighterir.com/public/aptam...
🔬 Identification of a novel biomarker targeted by Optimer for liver fibrosis therapies
🧬 Reduction in scar tissue formation in liver fibrosis models
👉 polaris.brighterir.com/public/aptam...
June 30, 2025 at 7:47 AM
We've made great progress in the development of the Optimer delivery vehicle targeting liver fibrosis:
🔬 Identification of a novel biomarker targeted by Optimer for liver fibrosis therapies
🧬 Reduction in scar tissue formation in liver fibrosis models
👉 polaris.brighterir.com/public/aptam...
🔬 Identification of a novel biomarker targeted by Optimer for liver fibrosis therapies
🧬 Reduction in scar tissue formation in liver fibrosis models
👉 polaris.brighterir.com/public/aptam...
Our new agreement with a global life science leader will see development of Optimer-Fc reagents for new immunohistochemistry reagents, with downstream licensing agreed.
Find out more here: polaris.brighterir.com/public/aptam...
Find out more here: polaris.brighterir.com/public/aptam...
June 25, 2025 at 6:08 AM
Our new agreement with a global life science leader will see development of Optimer-Fc reagents for new immunohistochemistry reagents, with downstream licensing agreed.
Find out more here: polaris.brighterir.com/public/aptam...
Find out more here: polaris.brighterir.com/public/aptam...
We're excited to announce the agreement of the second Optimer development programme with @unileveruki.bsky.social.
We look forward to working together to expand the potential of Optimer applications in personal care.
polaris.brighterir.com/public/aptam...
We look forward to working together to expand the potential of Optimer applications in personal care.
polaris.brighterir.com/public/aptam...
May 30, 2025 at 6:57 AM
We're excited to announce the agreement of the second Optimer development programme with @unileveruki.bsky.social.
We look forward to working together to expand the potential of Optimer applications in personal care.
polaris.brighterir.com/public/aptam...
We look forward to working together to expand the potential of Optimer applications in personal care.
polaris.brighterir.com/public/aptam...
Join us at this year's #BIO2025!
Our CEO, Arron Tolley, and CFO, Andrew Rapson, will be at this year’s BIO International Convention in Boston. Book a meeting to see how #Optimer can deliver better affinity ligands to support your pipeline.
letspartner.bio.org
Our CEO, Arron Tolley, and CFO, Andrew Rapson, will be at this year’s BIO International Convention in Boston. Book a meeting to see how #Optimer can deliver better affinity ligands to support your pipeline.
letspartner.bio.org
May 29, 2025 at 8:16 AM
Join us at this year's #BIO2025!
Our CEO, Arron Tolley, and CFO, Andrew Rapson, will be at this year’s BIO International Convention in Boston. Book a meeting to see how #Optimer can deliver better affinity ligands to support your pipeline.
letspartner.bio.org
Our CEO, Arron Tolley, and CFO, Andrew Rapson, will be at this year’s BIO International Convention in Boston. Book a meeting to see how #Optimer can deliver better affinity ligands to support your pipeline.
letspartner.bio.org
If you missed us at #ASGCT2025 last week, you can go to our website to download our poster, ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers: A Novel Approach for Fibrotic Liver Treatment’ which was presented at the conference.
go.aptamergroup.com/ASGCT-Poster
go.aptamergroup.com/ASGCT-Poster
May 23, 2025 at 8:23 AM
If you missed us at #ASGCT2025 last week, you can go to our website to download our poster, ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers: A Novel Approach for Fibrotic Liver Treatment’ which was presented at the conference.
go.aptamergroup.com/ASGCT-Poster
go.aptamergroup.com/ASGCT-Poster
Join our team next week at #ASGCT to see how Optimer can help with:
🎯Targeted delivery for your gene therapy
🧪Custom reagents to build better assays
🔍 Identify new biomarkers of disease
Don’t miss our poster
📊 ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers’
🎯Targeted delivery for your gene therapy
🧪Custom reagents to build better assays
🔍 Identify new biomarkers of disease
Don’t miss our poster
📊 ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers’
May 9, 2025 at 11:38 AM
Join our team next week at #ASGCT to see how Optimer can help with:
🎯Targeted delivery for your gene therapy
🧪Custom reagents to build better assays
🔍 Identify new biomarkers of disease
Don’t miss our poster
📊 ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers’
🎯Targeted delivery for your gene therapy
🧪Custom reagents to build better assays
🔍 Identify new biomarkers of disease
Don’t miss our poster
📊 ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers’
Meet us at #FoBUSA 📅 Apr 23–24, stand 1244! 🤝 Book time with Arron & Zeesharn + see poster 7 on Optimer® gene silencing in primary fibrotic hepatic stellate cells.
April 15, 2025 at 9:26 AM
Meet us at #FoBUSA 📅 Apr 23–24, stand 1244! 🤝 Book time with Arron & Zeesharn + see poster 7 on Optimer® gene silencing in primary fibrotic hepatic stellate cells.
Not all binders are equal. Learn how Optimer® binders are tailored for detection, purification & targeted delivery. Watch now: bit.ly/4bDGFwk
March 31, 2025 at 3:23 PM
Not all binders are equal. Learn how Optimer® binders are tailored for detection, purification & targeted delivery. Watch now: bit.ly/4bDGFwk
Reproducibility matters. Chemically synthesized aptamers offer the highest batch consistency for robust assays & reliable data. 🔬📊
🔗 aptamergroup.com/aptamers-offer-the-highest-batch-consistency-for-reliable-reproducibility/
🔗 aptamergroup.com/aptamers-offer-the-highest-batch-consistency-for-reliable-reproducibility/
March 28, 2025 at 11:07 AM
Reproducibility matters. Chemically synthesized aptamers offer the highest batch consistency for robust assays & reliable data. 🔬📊
🔗 aptamergroup.com/aptamers-offer-the-highest-batch-consistency-for-reliable-reproducibility/
🔗 aptamergroup.com/aptamers-offer-the-highest-batch-consistency-for-reliable-reproducibility/
📢 Our new knowledge centre is live! 🔍 Find the latest insights on Optimers for diagnostics, therapeutics & bioprocessing—now easier to search and explore. 🔬 Check it out: aptamergroup.com/knowledge-ce...
March 4, 2025 at 1:55 PM
📢 Our new knowledge centre is live! 🔍 Find the latest insights on Optimers for diagnostics, therapeutics & bioprocessing—now easier to search and explore. 🔬 Check it out: aptamergroup.com/knowledge-ce...
Today is #RareDiseaseDay. 350M+ people are affected, yet finding reliable biomarkers remains a challenge. Better tools can drive progress. 💜
February 28, 2025 at 10:12 AM
Today is #RareDiseaseDay. 350M+ people are affected, yet finding reliable biomarkers remains a challenge. Better tools can drive progress. 💜
ADCs are advancing precision medicine, though challenges persist. See how next-gen Optimer® binders enhance specificity, stability, and delivery for improved outcomes.
aptamergroup.com/expanding-ad...
aptamergroup.com/expanding-ad...
February 21, 2025 at 10:19 AM
ADCs are advancing precision medicine, though challenges persist. See how next-gen Optimer® binders enhance specificity, stability, and delivery for improved outcomes.
aptamergroup.com/expanding-ad...
aptamergroup.com/expanding-ad...
Wrapping up an inspiring California tour for our CEO, @ArronTolley! Arron engaged in productive discussions on how Optimer technology supports key projects. If you missed Arron or would like to learn more about how we can support your projects, please get in touch with our team.
February 19, 2025 at 9:15 AM
Wrapping up an inspiring California tour for our CEO, @ArronTolley! Arron engaged in productive discussions on how Optimer technology supports key projects. If you missed Arron or would like to learn more about how we can support your projects, please get in touch with our team.